Literature DB >> 6426961

Hyperammonemia and valproate-induced alterations of the state of consciousness. A report of 8 cases.

G Zaccara, M Paganini, R Campostrini, G Arnetoli, R Zappoli, F Moroni.   

Abstract

Sodium valproate was administered to 38 patients, admitted to our unit in the last 18 months, and chosen because they had: (1) poor control of their seizures; (2) therapeutic concentrations in their plasma of at least two major antiepileptic drugs. In 8 of them, a therapeutic dosage of VPA caused modifications of the state of consciousness ranging from coma to drowsiness and stupor. These patients also showed gastrointestinal disturbances, asterixis, ataxia, tremor and a worsening of EEG abnormalities. The side effects of the drug were constantly associated with increased concentration of blood ammonia. Better penetration of ammonia into the CNS of patients undergoing frequent seizures and possibly having imperfectly functioning biological barriers, could explain our observations. In view of the unusually high percentage of patients suffering from serious VPA side effects, it is probably advisable to carefully monitor ammonemia in the first few days of VPA therapy in every patient treated with multiple anticonvulsants.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6426961     DOI: 10.1159/000115687

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  9 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

2.  Valproic acid-associated encephalopathy.

Authors:  G L Jones; F Matsuo; J R Baringer; W H Reichert
Journal:  West J Med       Date:  1990-08

Review 3.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

4.  Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.

Authors:  M Paganini; G Zaccara; F Moroni; R Campostrini; L Bendoni; G Arnetoli; R Zappoli
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  State of stupor from valproic acid during chronic treatment: case report.

Authors:  S Gentile; C Buffa; C Ravetti; I Sacerdote
Journal:  Ital J Neurol Sci       Date:  1991-04

6.  Impairment of consciousness induced by valproate treatment following neurosurgical operation.

Authors:  J Landau; M Baulac; G Durand; A de Billy; J Philippon
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

7.  Valproate-induced hyperammonaemia in two epileptic identical twins.

Authors:  R Campostrini; G Zaccara; L Rossi; M Paganini; A Dorigotti; R Zappoli
Journal:  J Neurol       Date:  1985       Impact factor: 4.849

Review 8.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

Review 9.  Antiepileptic drug-induced pharmacodynamic aggravation of seizures: does valproate have a lower potential?

Authors:  Edouard Hirsch; Pierre Genton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.